Scholar Rock Holding Corporation will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4. The company is focused on developing apitegromab for patients with spinal muscular atrophy and other neuromuscular diseases. CEO David L. Hallal and the management team will represent the company at the event.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.